Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice. Issue 5 (25th July 2017)

• Record Type: Journal Article
• Authors: Tanaka, Toshihiro; Ueno, Miho; Nakashima, Yuta; Chinen, Shotaro; Sato, Eiichi; Masaki, Michio; Mogi, Ai; Sasaki, Hidenori; Tamura, Kazuo; Takamatsu, Yasushi
• Is Part Of: Thoracic cancer. Volume 8:Issue 5(2017)
• Page Start: 523
• Page End: 529
• Publication Date: 2017-07-25
• Subjects: Chemotherapy -- clinical practice -- eribulin -- metastatic breast cancer -- post‐treatment therapy; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.12482
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract : Background: Evidence of eribulin therapy for metastatic breast cancer (MBC) in clinical practice is not well documented. Methods: We retrospectively analyzed the safety and efficacy of eribulin in 29 MBC patients from 2011 to 2016 at Fukuoka University Hospital. Results: The median patient age, number of courses, total dose, and relative dose intensity were as follows: 65 years, five courses, 8.6 mg/m 2, and 75%, respectively. One patient achieved a complete response, (CR) six a partial response (PR), eight stable disease (SD) and 14 patients exhibited progressive disease. The objective response rate (ORR: CR + PR) was 24.1%, and the clinical benefit rate (CBR: CR + PR + SD) was 51.7%. The median progression‐free survival was 90 days (95% confidence interval [CI] 67–126) and median overall survival was 264 days (95% CI 198–357). In patients who previously received 2–4 regimens, the ORR was 28.5% and the CBR was 57.1%. In patients who received 5–12 regimens, the ORR was 20% and the CBR was 45%. Chemotherapy was administered to 20 patients (69%) after eribulin administration, and the median overall survival rate of cases that achieved greater than a PR was 1088 days. The most frequent treatment‐related grade 3/4 adverse events were neutropenia (55.2%), and febrile neutropenia (20.1%). Grade 3 peripheral neuropathy occurred in 13.8% of patients, but was not exacerbated even if present before treatment. Conclusion: Eribulin is effective for MBC patients who have received multiple chemotherapies. Neutropenia and febrile neutropenia may develop after heavy prior therapy.